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ABSTRACT
Background Patient and public involvement (PPI) in 
research is well- established in the UK. However, it can 
be challenging to introduce PPI to research communities 
where there is limited prior knowledge, experience or 
appreciation of PPI. We aimed to explore current PPI 
practices, experiences and ethical and operational 
challenges with PPI within our own research community in 
Austria, to inform strategies for supporting PPI in Austria 
going forward.
Methods We surveyed scientists at 21 research 
institutes of the Ludwig Boltzmann Gesellschaft (LBG) and 
representatives of 32 medical and university research 
ethics committees in Austria using online questionnaires. 
We analysed quantitative data using descriptive statistics, 
and we collated textual responses to open questions. We 
combined survey data with anecdotal evidence from our 
personal experience to summarise current challenges 
around implementing PPI in Austria.
Results Nineteen scientists from nine research 
institutes indicated generally positive attitudes towards 
PPI. However, the majority reported they rarely or never 
involved patients and members of the public in roles of 
consultation, collaboration or control in research. Six 
of eight ethics committees were unfamiliar with PPI. 
We discern five current challenges to implementing PPI 
in Austria: lack of knowledge and skills for PPI among 
scientists, scepticism about the usefulness of PPI, 
conflation of PPI with qualitative research, uncertainty 
about ethical requirements for PPI and uncertainty about 
publishing PPI activities.
Discussion We suggest that the provision of guidance 
about ethical requirements of PPI is a strategic priority. To 
address this, and following on from a recently introduced 
PPI training and grant scheme by the LBG, our surveys 
have initiated a dialogue with ethics committees and 
have informed the development of a checklist for ethical 
aspects of PPI.
Conclusion Our experiences may provide useful 
examples to others who seek to introduce or strengthen 
PPI practices within their own research communities.
BACKGROUND
Patient and public involvement (PPI) in 
research refers to the active involvement of 
members of the public in research processes 
and activities, with the aim that research 
is carried out ‘with’ or ‘by’ members of the 
public rather than ‘to’, ‘about’ or ‘for’ them.1 
The rationale for PPI includes a moral/
ethical dimension, based on the argument 
that those who have lived experience of the 
phenomenon being researched (eg, a health 
condition) should also have a voice in related 
research; a methodological dimension, 
claiming that PPI leads to greater relevance 
and credibility of research funding proposals 
and improved study designs, for example, 
with respect to acceptability of study proce-
dures to research participants; and a polit-
ical dimension, based on citizens’ rights and 
proposed advantages of alliances between 
researchers, patients and the public.2 Typical 
examples for PPI activities are involvement 
of patients and members of the public in the 
setting of research priorities, as co- applicants 
on research grant applications, as members 
of study steering or advisory groups, and as 
co- researchers.1
PPI has largely originated in the UK, where 
it was introduced during the 1990s and has 
been supported at the highest level of national 
research governance. The National Institute 
for Health Research (NIHR), the UK’s largest 
publicly funded health research funder, has 
made PPI a requirement for research grant 
applications.3 NIHR- sponsored national 
advisory organisation INVOLVE4 and other 
centres and support networks5 offer expertise 
to researchers for the implementation and 
advancement of PPI in healthcare research, 
and regulator Health Research Authority 
(HRA) publishes clear regulatory and ethical 
guidance on PPI for researchers.6
Other recent international develop-
ments are also promoting the inclusion of 
patients’ voices in research. The US Food 
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and Drug Administration Center for Drug Evaluation 
and Research is working on a series of guidance docu-
ments to support stakeholders (patients, researchers, 
medical product developers and others) in collecting and 
submitting patient experience data for medical product 
development and regulatory decision- making. The first 
document in this series, ‘Collecting Comprehensive and 
Representative Input’, was published in 2020.7 In Europe, 
a multistakeholder public–private partnership, the Euro-
pean Patients' Academy on Therapeutic Innovation 
(EUPATI), was established by the IMI- EUPATI project 
(2012–2017). This programme provides education and 
training to increase the capacity and capability of patients 
and patient representatives to understand and meaning-
fully contribute to medicines research and development.8 
EUPATI National Platforms mirror the EUPATI partner-
ship at national level and are currently set up in 22 Euro-
pean countries, including Austria.
Promoting PPI in Austria
In Austria, the independent non- profit research organi-
sation Ludwig Boltzmann Gesellschaft (LBG) champions 
PPI in clinical and healthcare research as part of its Open 
Innovation in Science (OIS) strategy. OIS is an umbrella 
term that describes the ‘opening up’ of the scientific 
process through various strategies, including citizen 
science, open access to scientific outputs and data, open 
innovation approaches from business and industry and 
PPI.9 To promote PPI, the LBG OIS Center initiated a 
multistakeholder process in 2019, co- developing a patient 
and public involvement and engagement (PPIE) ‘how to’ 
guide with researchers from various disciplines, patient 
organisations and citizen scientists.10 11 This laid the foun-
dation for a national PPI funding programme introduced 
in 2020 ( ppie. lbg. ac. at) which supports researchers 
to implement PPI activities with up to €60 000 over 12 
months. The call is embedded in continuous consultation 
and training on PPI, and peer support for researchers 
and members of the public to foster mutual learning. 
With these measures, the LBG OIS Center functions as a 
national point of contact and competence centre, aiming 
to embed meaningful PPI practices in the Austrian 
research landscape and offering support to researchers 
on an individual level.
In another OIS initiative, the LBG established two new 
Ludwig Boltzmann Institutes for Digital Health which 
commenced work in 2019. Both institutes were tasked 
with incorporating PPI throughout their programmes 
of research.12 Initial experiences made by researchers 
at these two institutes (STK, EK, MK- P, ES and AS- H 
among others), however, have surfaced challenges in 
implementing PPI practices, including lack of awareness 
and knowledge about the PPI concept in the local scien-
tific communities, lack of appreciation of the value of 
involving patients as ‘experts by experience’ and fear of 
violating research ethics if PPI activities are carried out 
without formal ethical approval. We therefore under-
took a scoping exercise and conducted surveys among 
researchers and representatives of research ethics commit-
tees in Austria. The aim was to explore current PPI prac-
tices, experiences and ethical and operational challenges 
with PPI, to gauge in how far our personal experiences 
might be reflected within our wider research commu-
nity and to draw insights which may inform strategies for 
supporting PPI in research in Austria going forward.
METHODS
Study design
In summer 2020, we conducted two online surveys to 
scope current PPI practices, experiences and ethical 
and operational challenges with PPI. In the design and 
conduct of the surveys we followed standard ethical 
research guidelines.
Data collection
Survey invitations were distributed by email and contained 
the access link, researcher contact details and information 
about the study purpose and publication of anonymised 
data. The surveys were open for 3 weeks, and reminders 
were emailed twice.
The first survey was distributed among postdoctoral 
researchers, principal investigators and OIS managers 
at 21 LBG- funded research institutes and groups. The 
questionnaire consisted of 10 items which were struc-
tured according to three aspects (three roles a patient 
or member of the public may take on in relation to 
research): participation (ie, entering a study as a study 
‘subject’), engagement/dissemination (ie, engaging 
with information about research activities and findings) 
and involvement (ie, making an active contribution to 
research processes and activities).1 9 We formulated ques-
tions with Likert- scale response options to explore how 
frequently respondents undertook certain activities such 
as involving patients and members of the public in the 
conceptualisation of research proposals. Additionally, 
we formulated semantic differential scale items to gauge 
respondents’ attitudes towards PPI, a multiple- choice 
item about ethical aspects, and two open questions about 
ethical aspects and general challenges around PPI.
The second survey addressed representatives (primary 
contact persons) from 23 medical and 9 university 
research ethics committees in Austria. This was a short 
questionnaire consisting of three multiple- choice items 
with optional free text answers. We asked whether the 
committee was familiar with the concept of PPI, how the 
committee dealt with queries regarding PPI and whether 
the committee was interested in joining a national PPI 
working group.
Analysis
We conducted descriptive statistical analyses for quanti-
tative survey data and collated textual responses to open 
questions. Using survey data to contextualise our personal 
experiences, we articulated five current challenges to 
implementing PPI practices in Austria.
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Patient and public involvement
Members of the public were not involved in the design 
and conduct of the surveys, because the immediate 
barriers to PPI we encountered in our work seemed to 
relate to awareness, knowledge and perceptions among 
researchers. Members of the public have been involved 
in the design and concept of the PPIE programme and 
funding model in 2019.
RESULTS
In our first survey, 19 scientists from nine different insti-
tutes/groups from disciplines across natural sciences, 
technical sciences, humanities, social sciences and health 
sciences indicated generally positive attitudes towards 
the involvement of patients and the public in research 
(figure 1). Eleven had previously conducted PPI activi-
ties, and eight had not (self- report). Respondents were 
generally active in disseminating research findings 
to patients or the public, via traditional media, social 
media, popular science events and other channels, which 
represents engagement/dissemination and not involve-
ment. Two- thirds indicated they rarely or never involved 
patients or members of the public in consultant roles. 
Three- quarters indicated they rarely or never involved 
patients or the public in the development and conduct 
of research studies. And almost all indicated they rarely 
or never involved patients or members of the public in 
research lead or study oversight roles. With respect to 
ethical aspects of PPI (especially when individuals are 
invited because of their ‘patient’ roles), those respon-
dents who had prior experience with PPI indicated that 
they tend to seek guidance from ethics committees, but 
not submit formal ethics applications for PPI activities.
In our second survey, we received responses from 8 of 
32 research ethics committees. Two respondents stated 
that committee members were familiar with PPI, and six 
respondents stated that they were not. The two commit-
tees familiar with PPI reported that they offered infor-
mation to researchers about PPI practices and provided 
statements in support of PPI activities. Seven respondents 
expressed interest in joining a national working group, 
with the aim to foster PPI by coordinating research gover-
nance and ethical practices (figure 2).
Points for attention
Our survey findings bring into focus and contextualise, 
and to some extent corroborate, the anecdotal evidence 
from our personal experience of introducing PPI prac-
tices at our Ludwig Boltzmann Institutes for Digital 
Health. Based on this we observe five challenges or 
‘points for attention’:Figure 1 Attitudes towards patient and public involvement 
among 19 researchers from nine different institutes/groups 
of the Ludwig Boltzmann Gesellschaft. Respondents rated 
seven attitudinal dimensions on 7- point semantic differential 
scales. Pie charts describe frequencies of ratings.
Figure 2 Responses (frequencies) from representatives of 
eight research ethics committees in Austria.
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1. While some researchers have considerable knowledge 
and experience of PPI, it appears that a large segment 
of the research community in Austria has limited 
awareness and knowledge of the PPI concept, let alone 
the necessary skills and experience for successfully 
conducting PPI.
2. We have encountered scepticism towards the useful-
ness and impact of PPI among LBG researchers and 
Austrian ethics committee members. Critics may ask 
for convincing evidence, especially when weighing up 
resources required for good quality PPI against expect-
ed outcomes.
3. There can be a conflation of PPI activities with qualita-
tive research. Particularly among quantitative research-
ers, PPI conversations with individuals or groups can 
be misunderstood as qualitative data collection.
4. We have noticed uncertainty and sometimes consider-
able concern among clinical researchers who are un-
familiar with PPI about ethical aspects of PPI. This is 
grounded in the (valid) ethical imperative that patient 
information for clinical research purposes must not 
be collected before ethical approval has been granted, 
but it neglects the difference between patients’ enrol-
ment as study participants versus patients’ involvement 
as PPI contributors. Especially PPI at the study concep-
tualisation and design stage, which takes place before 
a research ethics application is submitted, can create 
anxiety and fear of unethical conduct.
5. Lastly, there is uncertainty among researchers whether 
information collected through PPI activities should or 
could be published in peer- reviewed scientific articles.
DISCUSSION
Our online surveys showed that respondents have differing 
levels of experience with PPI, from very limited experi-
ence to actively and competently involving members of 
the public in several phases of the research cycle. In our 
first survey, responses outline a trend whereby the imple-
mentation of PPI activities decreases with increasing 
degree of involvement (from consultation to collabora-
tion to control).13 The sharing of decision- making and 
control over the research is particularly rare. This snap-
shot encourages us to further promote PPI on individual 
level (ie, offering training and facilitating exchange 
among researchers), and to introduce support structures 
on institutional and national level. In our second survey, 
most representatives from research ethics committees 
were unfamiliar with the PPI concept, but interested in 
discussing its ethical aspects. Acknowledging the potential 
for self- selection and social desirability bias in these surveys 
and limitations due to a low response rate from research 
ethics committees, our findings nevertheless indicate that 
awareness and knowledge of PPI should be addressed, 
and clear guidance on research governance and ethical 
requirements should be provided for the Austrian health-
care research community. To some extent, this requires a 
cultural shift and consensus building within the scientific 
community and among relevant stakeholders, such as 
funders, universities, research institutes and regional and 
federal medical research ethics committees.
Addressing points for attention
With respect to addressing the five challenges we formu-
late above, we offer the following considerations:
1. Researchers’ limited awareness, knowledge and skills 
for PPI have been highlighted as main stumbling 
blocks in the active involvement of members of the 
public in research.14 Signposting researchers to inter-
national scientific communities in which PPI is an es-
tablished and valued practice (also considering other 
descriptors which are used internationally to describe 
an approach that is similar to PPI in spirit, such as 
‘community engagement’15 or ‘patient- focused drug 
development’16) could emphasise the importance of 
PPI and increase motivation for researchers to acquire 
adequate knowledge and skills for PPI.
2. Demands for evidence of the usefulness of PPI are not 
straightforward to answer, as expected impacts of PPI 
are multifaceted, for example, benefiting research 
processes and outcomes, but also bringing about pos-
itive personal outcomes for PPI contributors and re-
searchers.17 A growing literature demonstrates these 
positive outcomes of PPI, although this evidence is also 
limited by methodological complexities.18 A recent 
meta- analysis of seven randomised controlled trials 
demonstrated that PPI interventions modestly but sig-
nificantly increased participant enrolment (OR 1.16, 
95% CI 1.01 to 1.34).19 Such high- level evidence will 
speak to proponents of the traditional hierarchy of ev-
idence paradigm. However, the value of evidence from 
qualitative and mixed methods reviews in describing 
nuanced and multifaceted impacts of PPI should not 
be neglected18 and should be considered for future 
research. PPI grant schemes should require that pro-
posals incorporate processes for evaluating the impact 
of PPI.
3. The conflation of PPI activities with qualitative re-
search has also been reported by others.20 There is 
a need to raise awareness and understanding of pa-
tients’ different roles, that is, patients as PPI contribu-
tors versus patients as research participants. Research 
institutions and ethics committees should provide 
guidance and training to support researchers in rec-
ognising these differences and in implementing PPI 
activities appropriately. Moreover, power differentials 
between researchers and PPI contributors need to be 
addressed,21 for example, by providing PPI contribu-
tors with adequate training opportunities and compen-
sation (monetary or other) for their time.
4. Authoritative guidance at national level to address eth-
ical concerns about PPI among healthcare researchers 
is needed. This should state unequivocally that PPI 
activities principally do not require formal review and 
approval by a research ethics committee, including PPI 
at the conceptualisation and design stage of a research 
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proposal. In the UK, for example, such guidance is 
provided by the HRA:
Do I need HRA ethical approval before I work with 
patients and the public? No. You do not need to sub-
mit an application to a Research Ethics Committee 
in order to involve the public in the planning or the 
design stage of research, even if the people involved 
are NHS [National Health Service] patients.22
At an international level and endorsed by the WHO, 
the International Ethical Guidelines for Health- related 
Research Involving Humans (Guideline 7: Community 
Engagement) provide a similarly helpful resource.15 
Although this does not clarify ethical requirements 
for PPI as explicitly as in the above example, the same 
message can be inferred:
Researchers and research ethics committees should 
be cognizant of the point at which the process of 
community engagement becomes a stage of formative 
research that itself requires ethics review. (CIOMS,15 
p26)
5. Uncertainty about publishing PPI in peer- reviewed ar-
ticles could be addressed by distinguishing three pub-
lication scenarios: the description of PPI in the meth-
ods section of scientific articles (this has recently been 
encouraged by the BMJ, signalling the importance at-
tributed to PPI by a world- leading medical journal),14 
the publication of PPI activities as research studies ‘in 
their own right’ and the publication of research stud-
ies about PPI.
Further developments
Following on from our survey findings, we identified the 
need for guidance about ethical requirements of PPI as 
a priority. As in the UK, formal ethical approval of PPI 
activities is currently not required by Austrian law if 
members of the public act as PPI contributors and not as 
study participants. In Austria, there is only a legal obliga-
tion for review by ethics committees in the case of clinical 
trial of drugs or medical devices and in the application 
of new medical methods and applied medical research 
to humans. National consensus and explicit guidance on 
this point would further raise awareness of researchers 
applying participatory research designs and PPI in its 
different forms—from consultation to collaboration to 
control—and their different ethical requirements.
To initiate this national consensus and promote change 
on a structural level, we invited a dialogue with Austrian 
research ethics committees about PPI. To date, five 
committees have joined an informal working group coor-
dinated by the LBG OIS Center and have supported the 
development of a checklist for ethical aspects of PPI.23 
We view this as a crucial step to inform about PPI and its 
ethical challenges, to align our vision and to address the 
conflation of PPI with qualitative research by outlining 
differences and ethical considerations around PPI also 
in ethics applications. The checklist is based on existing 
ethics guidelines in research10 and on the GRIPP-2 state-
ment for reporting PPI in research publications.24 The 
checklist could serve as best practice example and stan-
dard operating procedure for Austrian ethics committees 
in dealing with PPI. Applying the checklist to their own 
work, applicants may be asked to, for example, describe 
the role of patients and members of the public in their 
project, distinguish between study participation and 
involvement and highlight possible ethical issues. This 
could support quality assurance and implementation of 
standards for PPI and give researchers an opportunity to 
self- evaluate their ethical considerations around PPI.
CONCLUSION
This initiative for scoping PPI practices within the 
LBG research community in Austria has led to a wider 
discussion in the organisation and dialogue with stake-
holders, including research ethics committees. With 
our recently published checklist we have made prog-
ress towards providing ethical guidance for PPI in the 
Austrian research context, but we suggest that addressing 
consensus on governance and ethics of PPI remains a top 
strategic priority at a national structural level. Further 
strategic priorities are the ongoing provision of support 
at individual and institutional/organisational levels 
through PPI training opportunities and grant schemes 
to raise awareness and foster researchers’ knowledge and 
skills, and the building of the evidence base for PPI in the 
Austrian context through impact evaluations and formal 
research about PPI. It will be opportune and important 
to increase the involvement of patients and members of 
the public in the decision- making and delivery of these 
strategic measures. We envisage that the LBG OIS Center 
will continue to lead this work in collaboration with 
researchers, ethics committees, patients and members of 
the public, with the aim to achieve authentic and bene-
ficial implementation of PPI in the Austrian research 
community.
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